Little Andrew S, Shetter Andrew G, Shetter Mary E, Kakarla Udaya K, Rogers C Leland
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):522-7. doi: 10.1016/j.ijrobp.2008.08.048. Epub 2008 Dec 10.
To evaluate the clinical outcome of patients with surgically refractory trigeminal neuralgia (TN) treated with rescue gamma knife radiosurgery (GKRS).
Seventy-nine patients with typical TN received salvage GKRS between 1997 and 2002 at the Barrow Neurological Institute (BNI). All patients had recurrent pain following at least one prior surgical intervention. Prior surgical interventions included percutaneous destructive procedures, microvascular decompression (MVD), or GKRS. Thirty-one (39%) had undergone at least two prior procedures. The most common salvage dose was 80 Gy, although 40-50 Gy was typical in patients who had received prior radiosurgery. Pain outcome was assessed using the BNI Pain Intensity Score, and quality of life was assessed using the Brief Pain Inventory.
Median follow-up after salvage GKRS was 5.3 years. Actuarial analysis demonstrated that at 5 years, 20% of patients were pain-free and 50% had pain relief. Pain recurred in patients who had an initial response to GKRS at a median of 1.1 years. Twenty-eight (41%) required a subsequent surgical procedure for recurrence. A multivariate Cox proportional hazards model suggested that the strongest predictor of GKRS failure was a history of prior MVD (p=0.029). There were no instances of serious morbidity or mortality. Ten percent of patients developed worsening facial numbness and 8% described their numbness as "very bothersome."
GKRS salvage for refractory TN is well tolerated and results in long-term pain relief in approximately half the patients treated. Clinicians may reconsider using GKRS to salvage patients who have failed prior MVD.
评估采用挽救性伽玛刀放射外科手术(GKRS)治疗手术难治性三叉神经痛(TN)患者的临床疗效。
1997年至2002年期间,79例典型TN患者在巴罗神经学研究所(BNI)接受了挽救性GKRS治疗。所有患者在至少一次先前的手术干预后出现复发性疼痛。先前的手术干预包括经皮毁损手术、微血管减压术(MVD)或GKRS。31例(39%)患者至少接受过两次先前的手术。最常见的挽救剂量为80 Gy,不过先前接受过放射外科手术的患者通常采用40 - 50 Gy的剂量。使用BNI疼痛强度评分评估疼痛结果,使用简明疼痛问卷评估生活质量。
挽救性GKRS后的中位随访时间为5.3年。精算分析表明,在5年时,20%的患者疼痛消失,50%的患者疼痛缓解。最初对GKRS有反应的患者疼痛复发的中位时间为1.1年。28例(41%)患者因复发需要后续手术治疗。多变量Cox比例风险模型表明,GKRS失败的最强预测因素是先前接受过MVD的病史(p = 0.029)。没有出现严重并发症或死亡病例。10%的患者出现面部麻木加重,8%的患者称其麻木“非常困扰”。
GKRS挽救治疗难治性TN耐受性良好,约半数接受治疗的患者可获得长期疼痛缓解。临床医生可重新考虑使用GKRS挽救先前MVD失败的患者。